外用药物联合治疗银屑病的进展

摘要/Abstract

摘要： 银屑病的发病是多种因素共同作用的结果,其在病理上表现为角质形成细胞增生过度、炎症浸润和真皮乳头层的血管增生扩张,所以联合使用不同作用机制、不同作用靶位和不良反应无重叠的药物,可能会提高临床治疗效果和减少毒副作用。外用药物是治疗银屑病的主要手段之一,单独使用或配合其他治疗手段,可以使绝大多数银屑病患者的病情获得理想的临床控制。糖皮质激素(以下简称激素)、维生素D衍生物、维A酸和地蒽酚是目前国外治疗银屑病的最主要外用药物。将该4种药物相互联合外用,可以明显提高疗效和降低彼此的不良反应^[1]。

韩永智, 孙建方. 外用药物联合治疗银屑病的进展[J]. 中华皮肤科杂志, 2005, 38(3): 192-194.doi:

参考文献

[1] van de Kerkhof PC,Vissers WH.The topical treatment of psoriasis.Skin Pharmacol Appl Skin Physiol,2003,16;69-83.
[2] Liem WH,McCullough JL,Weinstein GD.Effectiveness of topical therapy for psoriasis;results of a national survey.Cutis.1995,55;306-310.
[3] Lebwohl M,Siskin SB,Epinette W,et al.A multicenter trial of calcipotriene ointment and halobetasol ointment compared with either agent alone for the treatment of psoriasis.J Am Acad Dermatol,1996,35;268-269.
[4] Kragballe K,Fogh K,Sogaard H.Long-term efficacy and tolerability of topical calcipotriol in psoriasis.Results of an open study.Acta Derm Venereol,1991,71;475-478.
[5] Levy J,Gassmuller J,Schroder G,et al.Comparison of the effects of calcipotriol,prednicarbate and clobetasol 17-propionate on normal skin assessed by ultrasound measurement of skin thickness.Skin Pharmacol,1994,7;231-236.
[6] Lebwohl M,Siskin SB,Epinette W,et al.A multicenter trial of calcipotriene ointment and halobetasol ointment compared with either agent alone for the treatment of psoriasis.J Am Acad Dermatol,1996,35;268-269.
[7] Katoh N,Kishimoto S.Combination of calcipotriol and clobetasol propionate as a premixed ointment for the treatment of psoriasis.Eur J Dermatol,2003,13;382-384.
[8] Douglas WS,Poulin Y,Decroix J,et al.A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris.Acta Derm Venereol,2002,82;131-135.
[9] Lahfa M,Mrowietz U,Koenig M,et al.Calcitriol ointment and clobetasol propionate cream;a new regimen for the treatment of plaque psoriasis.Eur J Dermatol,2003,13;261-265.
[10] Guenther L,Van de Kerkhof PC,Snellman E,et al.Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris;a randomized,doubleblind,vehicle-controlled clinical trial.Br J Dermatol,2002,147;316-323.
[11] Lebwohl M,Yoles A,Lombardi K,et al.Calcipotriene ointment and halobetasol ointment in the long-term treatment of psoriasis;effects on the duration of improvement.J Am Acad Dermatol,1998,39;447-450.
[12] Salmhofer W,Maier H,Soyer HP,et al.Double-blind,placebo-controlled,randomized,right-left study comparing calcipotriol monotherapy with a combined treatment of calcipotriol and diflucortolone valerate in chronic plaque psoriasis.Acta Derm Venereol Suppl (Stockh),2000,(211);5-8.
[13] Bruner CR,Feldman SR,Ventrapragada M,et al.A systematic review of adverse effects associated with topical treatments for psoriasis.Dermatol Online J,2003,9;2.
[14] van Rossum MM,van Erp PE,van de Kerkhof PC.Treatment of psoriasis with a new combination of calcipotriol and betamethasone dipropionate;a flow cytometric study.Dermatology,2001,203;148-152.
[15] Menter A.Pharmacokinetics and safety of tazarotene.J Am Acad Dermatol,2000,43;S31-S35.
[16] Lebwohl MG,Breneman DL,Goffe BS,et al.Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis.J Am Acad Dermatol,1998,39;590-596.
[17] Green L,Sadoff W.A clinical evaluation of tazarotene 0.1% gel,with and without a high- or mid-high-potency corticosteroid,in patients with stable plaque psoriasis.J Cutan Med Surg,2002,6;95-102.
[18] Poulin YP.Tazarotene 0.1% gel in combination with mometasone furoate cream in plaque psoriasis;a photographic tracking study.Cutis,1999,63;41-48.
[19] Gollnick H,Menter A.Combination therapy with tazarotene plus a topical corticosteroid for the treatment of plaque psoriasis.Br J Dermatol,1999,140 Suppl 54;18-23.
[20] Grattan CE,Christopher AP,Robinson M,et al.Double-blind comparison of a dithranol and steroid mixture with a conventional dithranol regimen for chronic psoriasis.Br J Dermatol,1988,119;623-626.
[21] Swinkels OQ,Prins M,Kucharekova M,et al.Combining lesional short-contact dithranol therapy of psoriasis with a potent topical corticosteroid.Br J Dermatol,2002,146;621-626.
[22] Swinkels OQ,Prins M,Tosserams EF,et al.The influence of a topical corticosteroid on short-contact high-dose dithranol therapy.Br J Dermatol,2001,145;63-69.
[23] Koo J,Cuffie CA,Tanner DJ,et al.Mometasone furoate 0.1%-salicylic acid 5% ointment versus mometasone furoate 0.1% ointment in the treatment of moderate-to-severe psoriasis;a multicenter study.Clin Ther,1998,20;283-291.
[24] Monastirli A,Georgiou S,Pasmatzi E,et al,Calcipotriol plus short-contact dithranol;a novel topical combination therapy for chronic plaque psoriasis.Skin Pharmacol Appl Skin Physiol,2002,15;246-251.
[25] Bowman PH,Maloney JE,Koo JY.Combination of calcipotriene (Dovonex) ointment and tazarotene (Tazorac) gel versus clobetasol ointment in the treatment of plaque psoriasis;a pilot study.J Am Acad Dermatol,2002,46;907-913.
[26] Hecker D,Worsley J,Yueh G,et al.In vitro compatibility of tazarotene with other topical treatments of psoriasis.J Am Acad Dermatol,2000,42;1008-1011.
[27] Patel B,Siskin S,Krasmien R,et al.Compatibility of calcipotriene with other topical medications.J Am Acad Dermatol,1998,38;1010-1011.
[28] Al-Suwaidan SN,Feldman SR.Clearance is not a realistic expectation of psoriasis treatment.J Am Acad Dermatol,2000,42;796-802.